IL111324A0 - CNTF family antagonists - Google Patents

CNTF family antagonists

Info

Publication number
IL111324A0
IL111324A0 IL11132494A IL11132494A IL111324A0 IL 111324 A0 IL111324 A0 IL 111324A0 IL 11132494 A IL11132494 A IL 11132494A IL 11132494 A IL11132494 A IL 11132494A IL 111324 A0 IL111324 A0 IL 111324A0
Authority
IL
Israel
Prior art keywords
cntf
family antagonists
cntf family
receptor component
antagonists
Prior art date
Application number
IL11132494A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22490270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL111324(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL111324A0 publication Critical patent/IL111324A0/xx
Priority to IL13532700A priority Critical patent/IL135327A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IL11132494A 1993-10-20 1994-10-18 CNTF family antagonists IL111324A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL13532700A IL135327A0 (en) 1993-10-20 2000-03-28 Cntf family antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/140,222 US5470952A (en) 1993-10-20 1993-10-20 CNTF and IL-6 antagonists

Publications (1)

Publication Number Publication Date
IL111324A0 true IL111324A0 (en) 1994-12-29

Family

ID=22490270

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11132494A IL111324A0 (en) 1993-10-20 1994-10-18 CNTF family antagonists

Country Status (16)

Country Link
US (2) US5470952A (ja)
EP (1) EP0726954B2 (ja)
JP (1) JP3961562B2 (ja)
CN (1) CN1138350A (ja)
AT (1) ATE187982T1 (ja)
AU (1) AU679579B2 (ja)
CA (1) CA2173846C (ja)
DE (1) DE69422304T3 (ja)
DK (1) DK0726954T4 (ja)
ES (1) ES2139759T5 (ja)
GR (1) GR3032777T3 (ja)
HK (1) HK1008346A1 (ja)
IL (1) IL111324A0 (ja)
PT (1) PT726954E (ja)
WO (1) WO1995011303A1 (ja)
ZA (1) ZA948242B (ja)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
EP0672144A1 (en) * 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6 receptor antagonists
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
AUPN024994A0 (en) * 1994-12-23 1995-01-27 Ludwig Institute For Cancer Research Assay and peptides for use therein
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
SE9701010D0 (sv) 1997-03-19 1997-03-19 Pharmacia & Upjohn Ab Antibody
JPH10324639A (ja) 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分として含有する感作ｔ細胞関与疾患の予防・治療剤
CA2318482C (en) 1998-01-23 2010-04-13 Immunex Corporation Il-18 receptors
US6410245B1 (en) 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
US7083949B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6864359B1 (en) * 1999-02-11 2005-03-08 Xencor Structure-based screening techniques for drug discovery
US6800460B1 (en) 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
ES2319958T3 (es) * 1999-03-11 2009-05-18 Schering Corporation Citoquinas de mamifero: reactivos y procedimientos asociados.
JP2003505514A (ja) * 1999-07-28 2003-02-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞生成を阻害する方法
US6673771B1 (en) * 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US6682739B1 (en) * 1999-07-28 2004-01-27 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis
WO2001016166A2 (en) 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
WO2001025277A1 (en) * 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
AU2002253942A1 (en) * 2001-02-12 2002-08-28 Michael Amling Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity
US6864047B2 (en) * 2001-03-29 2005-03-08 Mayo Foundation For Medical Education And Research IL1-β: a new target for myeloma therapy
US7595202B2 (en) * 2001-04-23 2009-09-29 Teruyuki Nagamune Analysis method using reporter (label) intermolecular interaction
CA2446189C (en) 2001-05-11 2011-10-18 Amgen, Inc. Peptides and related molecules that bind to tall-1
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
EP1421189A2 (en) * 2001-08-22 2004-05-26 Helix Biopharma Corp. Method and device for integrated protein expression, purification and detection
WO2003049673A2 (en) 2001-12-05 2003-06-19 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
ATE496066T1 (de) * 2002-10-25 2011-02-15 Us Gov Health & Human Serv Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta
FI20031050A (fi) * 2003-07-09 2005-01-10 Valtion Teknillinen Menetelmä proteiinien katkaisuun
US20050069987A1 (en) * 2003-09-30 2005-03-31 Daly Thomas J. Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
WO2006089251A2 (en) * 2005-02-17 2006-08-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SYNERGISTIC EFFECT OF TGF-β BLOCKADE AND IMMUNOGENIC AGENTS ON TUMORS
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007061981A2 (en) 2005-11-21 2007-05-31 Lumera Corporation Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
TWI381850B (zh) * 2005-12-30 2013-01-11 Pharmaessentia Corp 藥物與聚合物之共軛物
US8637469B2 (en) 2006-07-11 2014-01-28 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
DK2068889T3 (da) 2006-08-10 2020-02-03 Roy C Levitt Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom
WO2008113185A1 (en) 2007-03-19 2008-09-25 National Research Counsil Of Canada Antagonists of ligands and uses thereof
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
WO2010031168A1 (en) * 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
CA2891673A1 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EP3036262A4 (en) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
KR20180035884A (ko) 2015-08-04 2018-04-06 악셀레론 파마 인코포레이티드 골수증식성 장애를 치료하기 위한 방법
CN117503905A (zh) 2015-10-07 2024-02-06 阿佩利斯制药有限公司 给药方案
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2018195388A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
KR20240023201A (ko) 2017-05-04 2024-02-20 악셀레론 파마 인코포레이티드 Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JP3255699B2 (ja) * 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists

Also Published As

Publication number Publication date
AU7982794A (en) 1995-05-08
PT726954E (pt) 2000-04-28
HK1008346A1 (en) 1999-05-07
DK0726954T4 (da) 2007-10-01
US5470952A (en) 1995-11-28
CA2173846C (en) 2009-01-27
ATE187982T1 (de) 2000-01-15
ES2139759T3 (es) 2000-02-16
EP0726954B2 (en) 2007-05-30
WO1995011303A1 (en) 1995-04-27
DK0726954T3 (da) 2000-05-01
ZA948242B (en) 1995-06-13
CN1138350A (zh) 1996-12-18
ES2139759T5 (es) 2007-11-16
AU679579B2 (en) 1997-07-03
EP0726954B1 (en) 1999-12-22
GR3032777T3 (en) 2000-06-30
DE69422304T3 (de) 2007-12-27
US5844099A (en) 1998-12-01
JP3961562B2 (ja) 2007-08-22
DE69422304T2 (de) 2000-05-11
EP0726954A1 (en) 1996-08-21
JPH09504030A (ja) 1997-04-22
CA2173846A1 (en) 1995-04-27
DE69422304D1 (de) 2000-01-27

Similar Documents

Publication Publication Date Title
IL111324A0 (en) CNTF family antagonists
WO1995033059A3 (en) Receptor for oncostatin m
AU3659897A (en) Chemokine receptor antagonists and methods of use therefor
DE69738841D1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
GR3029561T3 (en) Pyrrolopyrimidines as crf antagonists.
ES2172535T3 (es) Antagonistas de los receptores de la endotelina.
SI0736525T1 (en) Benzonitriles as 5-HT agonists and antagonists
EP0488959A3 (en) New uses of competitive nmda receptor antagonists
IT8848075A0 (it) Anello di regolazione adatto all'uso di frizioni con compensazione dell'usura manuali e automatiche
AU5449194A (en) Combinations of angiotensin-ii receptor antagonists and diuretics
MX9606179A (es) Agonistas y antagonistas de los receptores del acido acetilcolina nicotinico de insectos para el control de endoparasitos.
AU9064191A (en) Use of angiotensin ii receptor antagonists in the treatment of atheroma
HK1032355A1 (en) Endothelin antagonist and beta receptor blocking agent as combined preparations.
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions
AU5627194A (en) New use of 5-ht3 receptor antagonists
AU3935897A (en) B1-bradykinin receptor antagonists and use thereof
MX9203778A (es) Antagonistas del receptor &-adrenergico y metodos de uso de los mismos.
AU3769089A (en) Alpha-adrenergic receptor antagonists
SG67345A1 (en) Sesquiterpenes their preparation and their use as inhibitors acting on the gaba-benzodiazepine receptor
ES2157261T3 (es) Familia de peptidos denominados xenoninas.
DE69004455T2 (de) Alpha-adrenergene Rezeptor-Antagonisten.
AU1394295A (en) New use of delta-opioid receptor antagonists
DE69004827T2 (de) Alpha-adrenergene Rezeptor-Antagonisten.
IE892801L (en) Antagonists of 5-ht and 5-ht3 receptors
AU5664194A (en) Progesterone receptor agonist and antagonists